MX337408B - Formulaciones topicas que tienen biodisponibilidad aumentada. - Google Patents
Formulaciones topicas que tienen biodisponibilidad aumentada.Info
- Publication number
- MX337408B MX337408B MX2009010170A MX2009010170A MX337408B MX 337408 B MX337408 B MX 337408B MX 2009010170 A MX2009010170 A MX 2009010170A MX 2009010170 A MX2009010170 A MX 2009010170A MX 337408 B MX337408 B MX 337408B
- Authority
- MX
- Mexico
- Prior art keywords
- topical formulations
- enhanced bioavailability
- lipophilic bioactive
- benefit
- utilized
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
- A61K8/355—Quinones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente descripción proporciona composiciones adecuadas para suministrar agentes lipofílicos bioactivos. Las composiciones pueden utilizarse para tratar numerosas enfermedades y padecimientos que pueden beneficiarse de la aplicación de un agente lipofílico bioactivo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91955407P | 2007-03-22 | 2007-03-22 | |
PCT/US2008/057786 WO2008116135A2 (en) | 2007-03-22 | 2008-03-21 | Topical formulations having enhanced bioavailability |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2009010170A MX2009010170A (es) | 2009-11-26 |
MX337408B true MX337408B (es) | 2016-03-03 |
Family
ID=39766784
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009010170A MX337408B (es) | 2007-03-22 | 2008-03-21 | Formulaciones topicas que tienen biodisponibilidad aumentada. |
MX2015000284A MX363435B (es) | 2007-03-22 | 2008-03-21 | Formulaciones topicas que tienen biodisponibilidad aumentada. |
MX2013012936A MX352434B (es) | 2007-03-22 | 2008-03-21 | Formulaciones topicas que tienen biodisponibilidad aumentada. |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015000284A MX363435B (es) | 2007-03-22 | 2008-03-21 | Formulaciones topicas que tienen biodisponibilidad aumentada. |
MX2013012936A MX352434B (es) | 2007-03-22 | 2008-03-21 | Formulaciones topicas que tienen biodisponibilidad aumentada. |
Country Status (10)
Country | Link |
---|---|
US (4) | US8454945B2 (es) |
EP (2) | EP3607937A1 (es) |
AU (2) | AU2008228764B2 (es) |
BR (1) | BRPI0809164B8 (es) |
CA (2) | CA2823407C (es) |
ES (1) | ES2755840T3 (es) |
MX (3) | MX337408B (es) |
NO (1) | NO20093032L (es) |
WO (1) | WO2008116135A2 (es) |
ZA (1) | ZA201400071B (es) |
Families Citing this family (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0752317A (ja) * | 1993-08-13 | 1995-02-28 | Asahi Shiyueebell Kk | 積層板 |
US7629384B2 (en) * | 1997-09-17 | 2009-12-08 | Strategic Science & Technologies, Llc | Topical delivery of L-arginine to cause beneficial effects |
US7914814B2 (en) | 1997-09-17 | 2011-03-29 | Strategic Science & Technologies, Llc | Topical delivery of arginine of cause beneficial effects |
US20080045909A1 (en) * | 2004-02-23 | 2008-02-21 | Strategic Science & Technologies, Llc. | Topical Delivery of a Nitric Oxide Donor to Improve and Skin Appearance |
US20110028548A1 (en) * | 2004-04-19 | 2011-02-03 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
US9226909B2 (en) | 2004-04-19 | 2016-01-05 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
WO2005102282A1 (en) * | 2004-04-19 | 2005-11-03 | Strategic Science & Technologies, Llc | Transdermal delivery of beneficial substances effected by a hostile biophysical environment |
CA2713943C (en) * | 2008-02-04 | 2018-10-23 | Teva Women's Health, Inc. | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof |
WO2009101412A1 (en) * | 2008-02-13 | 2009-08-20 | Cipla Limited | Topical pharmaceutical composition |
CA2721071C (en) * | 2008-04-11 | 2017-10-17 | Cytotech Labs, Llc | Methods and use of inducing apoptosis in cancer cells |
GB2465746B (en) * | 2008-11-21 | 2011-02-16 | Fortune Apex Dev Ltd | Pharmaceutical composition for topical application |
WO2010077723A1 (en) * | 2009-01-05 | 2010-07-08 | Hauck John F | Method for treating nocturia |
US9775802B2 (en) | 2009-03-24 | 2017-10-03 | Bausch & Lomb Incorporated | Method for preparing suspensions of low-solubility materials |
US20100247666A1 (en) * | 2009-03-24 | 2010-09-30 | Macleod Steven K | Method for Preparing Suspensions of Low-Solubility Materials |
US10058634B2 (en) | 2009-04-28 | 2018-08-28 | Surmodics, Inc. | Devices and methods for delivery of bioactive agents |
JP6081195B2 (ja) * | 2009-05-11 | 2017-02-15 | バーグ エルエルシー | エピメタボリックシフター、多次元細胞内分子、または環境影響因子を使用する腫瘍性障害の診断のための方法 |
WO2010151240A1 (en) * | 2009-06-24 | 2010-12-29 | Strategic Science & Technologies, Llc | Topical composition containing ibuprofen |
EP2445493A1 (en) | 2009-06-24 | 2012-05-02 | Strategic Science & Technologies, LLC | Topical composition containing naproxen |
US11684624B2 (en) | 2009-06-24 | 2023-06-27 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
AU2015203547B2 (en) * | 2009-06-24 | 2017-05-18 | Strategic Science & Technologies, Llc | Topical composition containing ibuprofen |
US20120251525A1 (en) * | 2009-06-30 | 2012-10-04 | Streeper Robert T | Method of utilizing azelaic acid esters to modulate communications mediated by biological molecules |
RU2532027C2 (ru) * | 2009-07-24 | 2014-10-27 | Мика Фарма Гезельшафт Фюр Ди Энтвиклюнг Унд Фермарктунг Фармацойтишер Продукте Мбх | Жидкие композиции, способные к пенообразованию и включающие активные средства, и способы их получения и разработки |
WO2011063531A1 (en) * | 2009-11-27 | 2011-06-03 | Nuvo Research Inc. | Topical ibuprofen formulations |
US20110150798A1 (en) * | 2009-12-21 | 2011-06-23 | Sarah Bacus | Compositions and methods for increasing cellular far and bleaching skin |
US20110150856A1 (en) | 2009-12-21 | 2011-06-23 | Sarah Bacus | Compositions and methods for treatment of vitiligo |
EP2544663B1 (en) * | 2010-03-12 | 2018-01-03 | Berg LLC | Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof |
CA2840339A1 (en) * | 2010-06-23 | 2011-12-29 | Brightside Innovations, Inc. | Lecithin carrier vesicles and methods of making the same |
KR20140005151A (ko) * | 2010-09-30 | 2014-01-14 | 세키스이 메디칼 가부시키가이샤 | 첩부제 |
CN103429246A (zh) * | 2010-12-29 | 2013-12-04 | 战略科学与技术有限责任公司 | 真菌感染和其它适应症的治疗的透皮递送 |
US20140004177A1 (en) * | 2010-12-29 | 2014-01-02 | Strategic Science & Technologies, Llc | Cox-2 inhibitors and related compounds, and systems and methods for delivery thereof |
CN103429247A (zh) * | 2010-12-29 | 2013-12-04 | 战略科学与技术有限责任公司 | 勃起功能障碍和其它适应症的治疗 |
WO2012092523A1 (en) * | 2010-12-29 | 2012-07-05 | Strategic Science & Technologies, Llc | Systems and methods for treatment of allergies and other indications |
CN103327965B (zh) * | 2011-01-25 | 2017-07-18 | 宝洁公司 | 脂质体和包含脂质体的个人护理组合物 |
US20160235669A1 (en) * | 2011-03-21 | 2016-08-18 | Food Industry Research And Development Institute | Process for preparing water dispersions containing high concentration of nano/submicron, hydrophobic, functional compounds and water dispersions obtainable therefrom |
CN103608323B (zh) | 2011-04-04 | 2016-08-17 | 博格有限责任公司 | 治疗中枢神经系统肿瘤的方法 |
US9861727B2 (en) | 2011-05-20 | 2018-01-09 | Surmodics, Inc. | Delivery of hydrophobic active agent particles |
US9757497B2 (en) | 2011-05-20 | 2017-09-12 | Surmodics, Inc. | Delivery of coated hydrophobic active agent particles |
US10213529B2 (en) | 2011-05-20 | 2019-02-26 | Surmodics, Inc. | Delivery of coated hydrophobic active agent particles |
PE20180414A1 (es) | 2011-06-17 | 2018-03-01 | Berg Llc | Composiciones farmaceuticas inhalables |
KR101808078B1 (ko) * | 2011-08-10 | 2017-12-13 | 주식회사 아이피어리스 | 리조레시친 및 글리세로포스포콜린을 이용한 리포좀 제제, 및 이를 포함하는 퍼스널 케어 조성물 |
JP5820206B2 (ja) | 2011-09-13 | 2015-11-24 | 日東電工株式会社 | 経皮吸収促進用組成物および貼付製剤 |
JP2013060393A (ja) * | 2011-09-13 | 2013-04-04 | Nitto Denko Corp | 経皮吸収促進用組成物および貼付製剤 |
JP5820207B2 (ja) | 2011-09-13 | 2015-11-24 | 日東電工株式会社 | 経皮吸収促進用組成物および貼付製剤 |
CN102366409B (zh) * | 2011-09-14 | 2013-03-20 | 海南灵康制药有限公司 | 一种尼扎替丁脂质体固体制剂 |
HRP20211377T1 (hr) | 2011-11-23 | 2022-01-07 | Therapeuticsmd, Inc. | Prirodne kombinirane hormonske supstitucijske formulacije i terapije |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10813897B2 (en) | 2011-12-27 | 2020-10-27 | Cmpd Licensing, Llc | Composition and method for compounded therapy |
US9468599B2 (en) * | 2011-12-27 | 2016-10-18 | Cmpd Licensing, Llc | Composition and method for compounded therapy |
US9962391B2 (en) | 2011-12-27 | 2018-05-08 | Cmpd Licensing, Llc | Composition and method for compounded therapy |
US11213500B2 (en) | 2011-12-27 | 2022-01-04 | Cmpd Licensing, Llc | Composition and method for compounded therapy |
US11213501B2 (en) | 2011-12-27 | 2022-01-04 | Cmpd Licensing, Llc | Composition and method for compounded therapy |
ES2761449T3 (es) | 2012-06-01 | 2020-05-19 | Berg Llc | Métodos de tratamiento de tumores sólidos que usan coenzima Q10 |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
CN102727438B (zh) * | 2012-06-29 | 2014-07-02 | 海南美兰史克制药有限公司 | 瑞格列奈脂质体固体制剂 |
US9937164B2 (en) | 2012-07-26 | 2018-04-10 | Camurus Ab | Opioid formulations |
US11246963B2 (en) | 2012-11-05 | 2022-02-15 | Surmodics, Inc. | Compositions and methods for delivery of hydrophobic active agents |
JP6438406B2 (ja) * | 2012-11-05 | 2018-12-12 | サーモディクス,インコーポレイテッド | 疎水性生理活性物質を送達するための組成物および方法 |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
WO2014117035A1 (en) | 2013-01-24 | 2014-07-31 | Transderm, Inc. | COMPOSITIONS FOR TRANSDERMAL DELIVERY OF mTOR INHIBITORS |
AU2014223226A1 (en) * | 2013-02-28 | 2015-09-03 | Precision Dermatology, Inc. | Topical formulations of corticosteroids with enhanced bioavailability |
US20140243300A1 (en) * | 2013-02-28 | 2014-08-28 | Precision Dermatology, Inc. | Controlling the Bioavailability of Active Ingredients in Topical Formulations |
US9511144B2 (en) | 2013-03-14 | 2016-12-06 | The Proctor & Gamble Company | Cosmetic compositions and methods providing enhanced penetration of skin care actives |
US20140276360A1 (en) * | 2013-03-15 | 2014-09-18 | Abbott Cardiovascular Systems Inc. | Electrophorectic drug coated balloon and conductive polymer coating |
US10933032B2 (en) | 2013-04-08 | 2021-03-02 | Berg Llc | Methods for the treatment of cancer using coenzyme Q10 combination therapies |
IL276423B2 (en) | 2013-09-04 | 2024-05-01 | Berg Llc | Pharmaceutical preparations containing coenzyme Q10 for use in cancer treatment |
CN103432073A (zh) * | 2013-09-11 | 2013-12-11 | 中国药科大学 | 一种肿瘤靶向纳米制剂及其制备方法 |
US20150083146A1 (en) * | 2013-09-23 | 2015-03-26 | Verso PV, LLC | Personal vaporizer liquid for emulsifying oil-soluble compounds and resins |
US20150174254A1 (en) | 2013-12-23 | 2015-06-25 | Mcneil-Ppc, Inc. | Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent |
US20150283163A1 (en) * | 2014-04-04 | 2015-10-08 | Organic Medical Ventures, L.L.C. | Muscle treatment composition and method making same |
CA2947767A1 (en) | 2014-05-22 | 2015-11-26 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
CA2951284A1 (en) | 2014-07-29 | 2016-02-04 | Therapeuticsmd, Inc. | Transdermal cream |
US11007161B1 (en) | 2014-12-31 | 2021-05-18 | Eric Morrison | Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films |
US10596117B1 (en) | 2014-12-31 | 2020-03-24 | Eric Morrison | Lipoleosomes as carriers for aromatic amide anesthetic compounds |
US10561627B2 (en) | 2014-12-31 | 2020-02-18 | Eric Morrison | Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films |
US10251871B2 (en) * | 2015-02-05 | 2019-04-09 | Memorial Sloan Kettering Cancer Center | Compositions and methods for treatment of edema |
US20160346219A1 (en) | 2015-06-01 | 2016-12-01 | Autotelic Llc | Phospholipid-coated therapeutic agent nanoparticles and related methods |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US9585867B2 (en) | 2015-08-06 | 2017-03-07 | Charles Everett Ankner | Cannabinod formulation for the sedation of a human or animal |
US9610242B2 (en) | 2015-08-18 | 2017-04-04 | Concept Labs, Inc. | Water-gel emulsion compositions and methods |
US20170106020A1 (en) * | 2015-10-19 | 2017-04-20 | Stanley James Harless | Anesthetic/analgesic composition |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
JP2019513709A (ja) | 2016-04-01 | 2019-05-30 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | ステロイドホルモン薬学的組成物 |
CN109641030B (zh) * | 2016-06-13 | 2023-05-16 | 优特埃合伙有限公司 | 用于调节阿片类戒断症状的方法和组合物 |
CN108066767A (zh) * | 2016-11-17 | 2018-05-25 | 北京科百大科技有限责任公司 | 一种稳定的含伊维菌素类药物的自乳化固体组合物 |
US10898446B2 (en) | 2016-12-20 | 2021-01-26 | Surmodics, Inc. | Delivery of hydrophobic active agents from hydrophilic polyether block amide copolymer surfaces |
WO2018129364A1 (en) | 2017-01-06 | 2018-07-12 | Palvella Therapeutics Llc | Anhydrous compositions of mtor inhibitors and methods of use |
KR102560269B1 (ko) * | 2017-03-24 | 2023-07-28 | 조이더마 아게 | 약제학적 조성물 |
JP7173992B2 (ja) | 2017-05-17 | 2022-11-17 | バーグ エルエルシー | 表皮水疱症の治療および防止におけるコエンザイムq10製剤の使用 |
IL272924B2 (en) | 2017-09-11 | 2024-01-01 | Atossa Therapeutics Inc | Methods for preparing and using endoxifen |
TW201919594A (zh) * | 2017-09-11 | 2019-06-01 | 美商艾陶莎基因有限公司 | 局部用組合物及治療方法 |
US20190083527A1 (en) | 2017-09-15 | 2019-03-21 | Ampersand Biopharmaceuticals, Inc. | Method of administration and treatment |
CN107522735A (zh) * | 2017-09-21 | 2017-12-29 | 安徽元创科技有限公司 | 以溶剂法生产低粘度磷脂产品的方法 |
US11000513B2 (en) | 2018-07-02 | 2021-05-11 | Palvella Therapeutics, Inc. | Anhydrous compositions of mTOR inhibitors and methods of use |
AU2020272127B2 (en) | 2019-04-12 | 2022-12-08 | Ecolab Usa Inc. | Antimicrobial multi-purpose cleaner and methods of making and using the same |
US11253518B2 (en) * | 2019-08-07 | 2022-02-22 | Aneira Pharma, Inc. | Methods and compositions for the treatment of hair loss |
US20210322339A1 (en) | 2019-11-20 | 2021-10-21 | Berg Llc | Combination therapy of coenzyme q10 and radiation for treatment of glioma |
CN111166735B (zh) * | 2020-01-15 | 2023-08-18 | 延边大学 | 邻苯二甲酸-双-(2-乙基庚基)酯在抑制脂肪蓄积中的应用 |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
CN111407893A (zh) * | 2020-04-26 | 2020-07-14 | 深圳大学 | p38-MAPK信号通路的抑制剂在制备用于治疗鼻咽癌的药物中的应用 |
WO2021222870A2 (en) * | 2020-04-30 | 2021-11-04 | Purser Danny C | Superoxide dismutase compositions and methods |
US11179353B1 (en) * | 2020-09-22 | 2021-11-23 | Rythera Therapeutics, Inc. | Composition and method for prevention and treatment of radiation dermatitis |
WO2022155341A1 (en) * | 2021-01-13 | 2022-07-21 | Dyve Biosciences, Inc. | Transdermal formulations for phosphodiesterase-5 inhibitors |
KR20230000506A (ko) * | 2021-06-24 | 2023-01-03 | 주식회사 종근당 | 칸데사르탄, 암로디핀 및 아트로바스타틴을 포함하는 약제학적 복합제제 |
BE1030538B1 (nl) * | 2022-05-18 | 2023-12-19 | Bogaert Gina Van | Liposomaal preparaat met ingekapselde hormonen, werkwijze voor de productie en gebruik ervan |
CN114939115B (zh) * | 2022-06-09 | 2023-07-25 | 上海智同医药科技有限公司 | 一种药物组合物及由其制成的微丸和胶囊 |
CN115069241A (zh) * | 2022-06-10 | 2022-09-20 | 同济大学 | 膦辅助补丁调制负载性金纳米簇及制备方法和催化应用 |
Family Cites Families (207)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4525350A (en) | 1975-02-20 | 1985-06-25 | The New England Institute, Inc. | Methods of stimulating host defense system with coenzymes Q4 to Q.sub.1 |
IT1157269B (it) | 1982-03-19 | 1987-02-11 | Seuref Ag | Nuove formulazioni farmaceutiche contenenti il coenzima q10 adatte per la somministrazione topica |
JPS58201711A (ja) | 1982-05-19 | 1983-11-24 | Eisai Co Ltd | ユビデカレノン含有リポソ−ム被覆体 |
US4515736A (en) | 1983-05-12 | 1985-05-07 | The Regents Of The University Of California | Method for encapsulating materials into liposomes |
US4895727A (en) | 1985-05-03 | 1990-01-23 | Chemex Pharmaceuticals, Inc. | Pharmaceutical vehicles for exhancing penetration and retention in the skin |
US5651991A (en) | 1987-10-28 | 1997-07-29 | Nippon Shinyaku Co. Ltd. | Drug carriers |
GB8811410D0 (en) * | 1988-05-13 | 1988-06-15 | Unilever Plc | Treatment of skin disorders |
US5015483A (en) | 1989-02-09 | 1991-05-14 | Nabisco Brands, Inc. | Liposome composition for the stabilization of oxidizable substances |
US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
US5962243A (en) | 1990-04-18 | 1999-10-05 | Board Of Regents, The University Of Texas System | Methods for the identification of farnesyltransferase inhibitors |
EP0510165B1 (fr) | 1990-11-14 | 1995-01-25 | L'oreal | Composes amphiphiles non-ioniques derives du glycerol, leur procede de preparation, composes intermediaires correspondants et compositions contenant lesdits composes |
SE502569C2 (sv) | 1991-05-31 | 1995-11-13 | British Tech Group | Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit |
US5378461A (en) | 1991-07-12 | 1995-01-03 | Neigut; Stanley J. | Composition for the topical treatment of skin damage |
US6461593B1 (en) | 1992-02-19 | 2002-10-08 | Biomedical And Clinical Research | Therapy with coenzyme Q10 to reduce subgingival microorganisms in patients with periodontal disease |
WO1993016704A1 (en) | 1992-02-24 | 1993-09-02 | East Carolina University | Method of inhibiting carcinogenesis by treatment with dehydroepiandrosterone and analogs thereof |
US5602184A (en) | 1993-03-03 | 1997-02-11 | The United States Of America As Represented By Department Of Health And Human Services | Monoterpenes, sesquiterpenes and diterpenes as cancer therapy |
EP0616801B1 (de) | 1993-03-24 | 1998-05-27 | Novartis AG | Verfahren zur Herstellung einer Liposomendispersion im Hochdruckbereich |
US7083572B2 (en) | 1993-11-30 | 2006-08-01 | Bristol-Myers Squibb Medical Imaging, Inc. | Therapeutic delivery systems |
DE4410238A1 (de) | 1994-03-25 | 1995-09-28 | Beiersdorf Ag | Hautpflegemittel |
US20020049422A1 (en) | 1994-03-31 | 2002-04-25 | Brewitt Barbara A. | Homeopathic preparations |
AU4510596A (en) | 1994-12-06 | 1996-06-26 | National Research Council Of Canada | Water soluble ubiquinone compositions, prodrugs, and methods relating thereto |
US6005086A (en) | 1995-01-13 | 1999-12-21 | The Salk Institute For Biological Studies | Farnesoid activated receptor polypeptides, and nucleic acid encoding the same |
DE19537027A1 (de) | 1995-10-05 | 1997-04-10 | Beiersdorf Ag | Hautpflegemittel für alte Haut |
US5944012A (en) | 1996-03-25 | 1999-08-31 | Pera; Ivo E. | Method for dispensing antioxidant vitamins by inhalation background of the invention |
DE19615577A1 (de) | 1996-04-19 | 1997-10-23 | Beiersdorf Ag | Verwendung von Salicin als antiirritativer Wirkstoff in kosmetischen und topischen dermatologischen Zubereitungen |
US5891465A (en) | 1996-05-14 | 1999-04-06 | Biozone Laboratories, Inc. | Delivery of biologically active material in a liposomal formulation for administration into the mouth |
GB9625895D0 (en) | 1996-12-13 | 1997-01-29 | Riley Patrick A | Novel compound useful as therapeutic agents and assay reagents |
ES2159938T3 (es) | 1997-02-11 | 2001-10-16 | Mse Pharmazeutika Gmbh | Preparados transdermicos, orales e intravenosos de 2,3-dimetoxi-5-metil-6-decaprenil-1,4-benzoquinona. |
US20040228910A1 (en) | 1997-02-11 | 2004-11-18 | Mse Pharmazeutika Gmbh | Transdermal, oral and intravenous formulations of 2, 3-dimethoxy-5-methyl-6-decaprenyl-1, 4-benzoquinone |
EP1007018B1 (de) | 1997-02-12 | 2003-10-08 | MSE Pharmazeutika GmbH | Verwendung von 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzochinon inder behandlung von tinnitus |
US6599513B2 (en) | 1997-05-27 | 2003-07-29 | Sembiosys Genetics Inc. | Products for topical applications comprising oil bodies |
US6372234B1 (en) | 1997-05-27 | 2002-04-16 | Sembiosys Genetics Inc. | Products for topical applications comprising oil bodies |
CA2303200A1 (en) | 1997-09-04 | 1999-03-11 | Brian C. Keller | Oral liposomal delivery system |
EP1027045A4 (en) | 1997-10-31 | 2004-12-08 | Arch Dev Corp | METHODS AND COMPOSITIONS FOR REGULATING 5-ALPHA-REDUCTASE ACTIVITY |
US6696484B2 (en) | 1997-10-31 | 2004-02-24 | University Of Chicago Office Of Technology And Intellectual Property | Method and compositions for regulation of 5-alpha reductase activity |
WO1999026657A1 (en) | 1997-11-25 | 1999-06-03 | Musc Foundation For Research Development | Inhibitors of nitric oxide synthase |
US6372880B1 (en) | 1997-12-25 | 2002-04-16 | Mitsui Chemicals, Inc. | Copolymer and process for preparing the same |
CA2736981A1 (en) | 1998-04-14 | 1999-10-21 | Kyowa Hakko Bio Co., Ltd. | Process for producing isoprenoid compounds by microorganisms |
US6503523B2 (en) | 1998-05-07 | 2003-01-07 | Gs Development A.B. | Skin care agents containing combinations of active agents consisting of vitamin a derivatives and UBI- or plastoquinones |
DE19828081C2 (de) | 1998-06-24 | 2000-08-10 | Cognis Deutschland Gmbh | W/O-Emulsionsgrundlagen |
US6623746B1 (en) | 1998-07-16 | 2003-09-23 | Cognis Deutschland Gmbh & Co. Kg | PIT emulsions, methods of softening paper using the same, and paper substrates treated therewith |
US6048886A (en) | 1998-10-05 | 2000-04-11 | Neigut; Stanley | Compositions and delivery systems for the topical treatment of psoriasis and other conditions of the skin |
US20040034107A1 (en) | 1999-02-11 | 2004-02-19 | Mse Pharmazeutika Gmbh | Ubiquinone Qn for the treatment of pain |
US20030104048A1 (en) | 1999-02-26 | 2003-06-05 | Lipocine, Inc. | Pharmaceutical dosage forms for highly hydrophilic materials |
US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6482943B1 (en) | 1999-04-30 | 2002-11-19 | Slil Biomedical Corporation | Quinones as disease therapies |
US6803193B1 (en) | 1999-06-23 | 2004-10-12 | The Penn State Research Foundation | Methods to identify modulators of the mevalonate pathway in sterol synthesis |
ATE304344T1 (de) | 1999-07-02 | 2005-09-15 | Cognis Ip Man Gmbh | Mikrokapseln - iii |
US6630160B1 (en) | 1999-09-07 | 2003-10-07 | Genetic Services Management, Inc. | Process to modulate disease risk with doses of a nutraceutical |
US20030104080A1 (en) | 1999-09-07 | 2003-06-05 | Singh Parashu Ram | Topical urea composition |
US20060204458A1 (en) * | 2000-10-26 | 2006-09-14 | Holloway William D Jr | Anti-aging methods and composition |
US20030180352A1 (en) | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US7250174B2 (en) | 1999-12-07 | 2007-07-31 | Schott Ag | Cosmetic, personal care, cleaning agent, and nutritional supplement compositions and methods of making and using same |
US7083780B2 (en) | 1999-12-11 | 2006-08-01 | Cognis Deutschland Gmbh & Co. Kg | Cosmetic composition containing hydroxyethers |
KR20020063914A (ko) | 1999-12-20 | 2002-08-05 | 코니스 프랑스, 에스.에이. | 화장용 및/또는 약학용 제제 |
FR2804864B1 (fr) | 2000-02-11 | 2003-04-04 | Serobiologiques Lab Sa | Extraits de residus issus de la fabrication du vin et leur utilisation en cosmetique ou pharmacologie |
US20020044913A1 (en) | 2000-02-11 | 2002-04-18 | Hamilton Nathan D. | Cosmetics to support skin metabolism |
DE10007322A1 (de) | 2000-02-17 | 2001-08-23 | Cognis Deutschland Gmbh | Perlglanzmittel |
DE50115609D1 (de) | 2000-02-17 | 2010-10-14 | Basf Se | Wässrige Dispersion wasserunlöslicher organischer UV-Filtersubstanzen |
FR2805464B1 (fr) | 2000-02-25 | 2003-02-14 | Serobiologiques Lab Sa | Preparations cosmetiques contenant des extraits de la plante mourera fluviatilis |
DE10009996B4 (de) | 2000-03-02 | 2005-10-13 | Cognis Ip Management Gmbh | Feststoffgranulate mit monodisperser Korngrößenverteilung, ein Verfahren zu ihrer Herstellung sowie ihre Verwendung |
US6447760B2 (en) * | 2000-05-08 | 2002-09-10 | Playtex Products, Inc. | Sunless tanning compositions |
US6468552B1 (en) | 2000-06-02 | 2002-10-22 | Neutrogena Corporation | Stabilized compositions containing oxygen-labile active agents |
DE10031703A1 (de) | 2000-06-29 | 2002-01-10 | Beiersdorf Ag | Verwendung von Calcium freisetzenden oder bindenden Substanzen zur gezielten Schächung oder Stärkung der Barrierefunktion der Haut |
EP1170015A1 (de) | 2000-07-06 | 2002-01-09 | Laboratoires Serobiologiques(Societe Anonyme) | Verwendung von Extrakten des Pilzes Grifola frondosa |
DE10033022A1 (de) | 2000-07-07 | 2002-01-17 | Cognis Deutschland Gmbh | Aerosole |
DE10034619A1 (de) | 2000-07-17 | 2002-01-31 | Cognis Deutschland Gmbh | Aniontensidfreie niedrigviskose Trübungsmittel |
DE10036655A1 (de) | 2000-07-26 | 2002-02-07 | Basf Ag | Kosmetische oder dermatologische Zubereitungen zur Vermeidung von Hautschädigungen durch Peroxide |
DE10036799A1 (de) | 2000-07-28 | 2002-02-07 | Beiersdorf Ag | Neues Mittel zur Behandlung der Haare und der Kopfhaut |
US7198801B2 (en) | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
FR2813195B1 (fr) | 2000-08-29 | 2003-04-04 | Serobiologiques Lab Sa | Utilisation d'extraits de la plante cassia alata dans des produits de soin |
DE10048260A1 (de) | 2000-09-29 | 2002-04-11 | Beiersdorf Ag | Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Aminoguanidin und/oder dessen Derivaten und Strukturanaloga zur Hautaufhellung von Altersflecken und/oder zur Verhinderung der Hautbräunung, insbesondere der durch UV-Strahlung hervorgerufenen Hautbräunung |
DE10053328A1 (de) | 2000-10-27 | 2002-05-08 | Cognis Deutschland Gmbh | Kosmetische Zubereitungen |
US20070003536A1 (en) | 2000-11-21 | 2007-01-04 | Zimmerman Amy C | Topical skin compositions, their preparation, and their use |
DE10064818A1 (de) | 2000-12-22 | 2002-06-27 | Basf Ag | Verwendung von Chroman-Derivaten in kosmetischen oder dermatologischen Zubreitungen |
US6806069B2 (en) | 2001-01-09 | 2004-10-19 | Pharmachem Laboratories, Inc. | Ubiquinone composition and methods related thereto |
FR2819414A1 (fr) | 2001-01-15 | 2002-07-19 | Cognis France Sa | Preparations cosmetiques et/ou pharmaceutiques comprenant des extraits de plantes dites a resurrection |
NL1017205C2 (nl) | 2001-01-26 | 2002-07-29 | Adriaan Emanuel Hendricus Wiel | Medicinale en cosmetische toepassing van hop en co-enzym Q10. |
DE10113053A1 (de) | 2001-03-15 | 2002-09-19 | Beiersdorf Ag | Selbstschäumende oder schaumförmige Zubereitungen mit anorganischen Gelbildnern und organischen Hydrololloiden |
DE10113050A1 (de) | 2001-03-15 | 2002-09-19 | Beiersdorf Ag | Selbstschäumende oder schaumförmige Zubereitungen organischen Hydrokolloiden |
DE10113046A1 (de) | 2001-03-15 | 2002-09-26 | Beiersdorf Ag | Selbstschäumende schaumförmige Zubereitungen mit organischen Hydrokolliden und partikulären hydrophobisierten und/oder ölabsorbierenden Festkörpersubstanzen |
EP1243252B1 (fr) | 2001-03-23 | 2006-05-24 | L'oreal | Composition pour le peau, contenant des fibres et des ubiquinones |
US20030031688A1 (en) | 2001-04-02 | 2003-02-13 | Dipak Ghosh | Cosmetic composition with improved skin moisturizing properties |
US6727234B2 (en) | 2001-04-03 | 2004-04-27 | University Of Iowa Research Foundation | Isoprenoid analog compounds and methods of making and use thereof |
DE10118269A1 (de) | 2001-04-12 | 2002-10-17 | Cognis Deutschland Gmbh | Kosmetische Zubereitungen |
US6686485B2 (en) | 2001-04-19 | 2004-02-03 | Daniel David West | Synthesis of coenzyme Q10, ubiquinone |
US6582723B2 (en) | 2001-05-03 | 2003-06-24 | Wayne F. Gorsek | Cancer immune composition for prevention and treatment of individuals |
JP3742602B2 (ja) | 2001-05-09 | 2006-02-08 | 株式会社カネカ | 還元型補酵素qの安定な溶液 |
JP4603192B2 (ja) | 2001-05-10 | 2010-12-22 | 株式会社カネカ | 毛髪頭皮用組成物 |
DE10123771B4 (de) | 2001-05-16 | 2019-01-10 | Beiersdorf Ag | Verwendung von Elektrolyten zur Stärkung der Barrierefunktion der Haut |
EP1260212A1 (de) | 2001-05-21 | 2002-11-27 | Cognis France S.A. | Kosmetische Mittel |
EP1262167A1 (de) | 2001-06-01 | 2002-12-04 | Cognis France S.A. | Kosmetische Zubereitungen enthaltend ein Extrakt von keimenden Pflanzen |
US7091241B2 (en) | 2001-06-01 | 2006-08-15 | Summa Health System | Nontoxic potentiation/sensitization of cancer therapy by supplementary treatment with combined vitamins C and K3 |
US6506915B1 (en) | 2001-06-14 | 2003-01-14 | Daniel David West | Synthesis of coenzyme Q10 ubiquinone |
FR2826017B1 (fr) | 2001-06-15 | 2004-06-11 | Cognis France Sa | Melanges de tensioactifs |
SE0102380D0 (sv) | 2001-07-02 | 2001-07-02 | Macronova Ab | Kräm för behandling av åldersförändringar i huden hos människa |
DE10133198A1 (de) | 2001-07-07 | 2003-01-23 | Beiersdorf Ag | Kreatin enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut |
JP2003020495A (ja) | 2001-07-10 | 2003-01-24 | Cognis Japan Ltd | 油脂組成物 |
CH695085A5 (de) | 2001-07-13 | 2005-12-15 | Mibelle Ag Cosmetics | Formulierungen zur Pflege der Haut nach Laserbehandlungen und/oder chemischen Peelings und Verwendung der Formulierungen. |
TWI235146B (en) | 2001-07-16 | 2005-07-01 | Kaneka Corp | Method of stabilizing reduced coenzyme q10 and method of acidic crystallization |
JP2004536136A (ja) | 2001-07-27 | 2004-12-02 | エヌ・ヴイ・ヌートリシア | 敗血症の防止及び/又は処置のための経腸組成物 |
EP1281392A1 (de) | 2001-08-02 | 2003-02-05 | Cognis France S.A. | Kosmetische und/oder pharmaceutische Zubereitungen enthaltend Pflanzenextrakte |
DE10139580A1 (de) | 2001-08-10 | 2003-02-20 | Beiersdorf Ag | Kosmetische und dermatologische Zubereitungen in Form von O/W-Emulsionen mit einem Gehalt an Sterinen und/oder C12-C40-Fettsäuren |
DE10143964A1 (de) | 2001-09-07 | 2003-03-27 | Basf Ag | Emulgatorarme oder emulgatorfreie Systeme vom Typ Öl-in-Wasser mit einem Gehalt an Stabilisatoren und einem aminosubstituierten Hydroxybenzophenon |
DE10143963A1 (de) | 2001-09-07 | 2003-03-27 | Basf Ag | Kosmetische und dermatologische Zubereitungen in Form von W/O-Emulsionen, enthaltend ein aminosubstituiertes Hydroxybenzophenon |
DE10143962A1 (de) | 2001-09-07 | 2003-03-27 | Basf Ag | Kosmetische und dermatologische Zubereitungen in Form von O/W-Emulsionen, enthaltend ein aminosubstituiertes Hydroxybenzophenon |
AU2002339555B2 (en) | 2001-09-18 | 2007-03-01 | Ciba Specialty Chemicals Holding Inc. | Use of guaiol for treating the skin |
DE10150725A1 (de) | 2001-10-13 | 2003-04-17 | Cognis Deutschland Gmbh | Aniontensidfreie niedrigviskose Trübungsmittel |
US7560123B2 (en) | 2004-08-12 | 2009-07-14 | Everett Laboratories, Inc. | Compositions and methods for nutrition supplementation |
US20060039956A1 (en) | 2001-10-26 | 2006-02-23 | Hermann Hensen | Impregnating solution for cosmetic cloths |
US6753325B2 (en) | 2001-11-06 | 2004-06-22 | The Quigley Corporation | Composition and method for prevention, reduction and treatment of radiation dermatitis |
US20030105031A1 (en) | 2001-11-06 | 2003-06-05 | Rosenbloom Richard A. | Methods for the treatment of skin disorders |
DE10155769A1 (de) | 2001-11-14 | 2003-05-22 | Cognis Deutschland Gmbh | Kosmetische und/oder pharmazeutische Emulsionen |
DE10160682A1 (de) | 2001-12-11 | 2003-06-18 | Cognis Deutschland Gmbh | Emollients und kosmetische Zusammensetzungen |
US6652891B2 (en) | 2001-12-12 | 2003-11-25 | Herbasway Laboratories, Llc | Co-enzyme Q10 dietary supplement |
DE10162351A1 (de) | 2001-12-18 | 2003-07-03 | Cognis Deutschland Gmbh | Kosmetische und/oder pharmazeutische Emulsionen |
DE10162026A1 (de) | 2001-12-18 | 2003-07-03 | Cognis Deutschland Gmbh | Hochkonzentriert fließfähige Perlglanzkonzentrate |
ITRM20010755A1 (it) | 2001-12-20 | 2003-06-20 | Simonelli Giuseppe | Uso del chinone q10 per il trattamento delle malattie oculari. |
US20030129253A1 (en) | 2002-01-03 | 2003-07-10 | Milley Christopher J. | Stable aqueous suspension |
TW200302056A (en) | 2002-01-18 | 2003-08-01 | Kaneka Corp | Method for stabilizing reduced coenzyme Q10 and composition therefor |
US20050118209A1 (en) | 2002-01-18 | 2005-06-02 | Basf Aktiengesellschaft | Cosmetic or dermatological preparations for preventing damages to skin caused by peroxides |
CN100473374C (zh) | 2002-01-31 | 2009-04-01 | 西巴特殊化学品控股有限公司 | 微粉颜料混合物 |
CA2473228C (en) | 2002-02-12 | 2010-12-14 | Dsm Ip Assets B.V. | Sunscreen compositions as well as dihydropyridines and dihydropyranes |
CN1633245A (zh) | 2002-02-14 | 2005-06-29 | Dsmip资产有限公司 | 水可分散的辅酶q10干粉 |
EP1340486A1 (de) | 2002-03-01 | 2003-09-03 | Cognis France S.A. | Verwendung von Zuckerestern |
US20030167556A1 (en) * | 2002-03-05 | 2003-09-11 | Consumers Choice Systems, Inc. | Methods and devices for transdermal delivery of anti-aging compounds for treatment and prevention of facial or neck skin aging |
DE10254315A1 (de) | 2002-03-15 | 2003-10-02 | Cognis Deutschland Gmbh | Emollients und kosmetische Zubereitungen |
DE10212528A1 (de) | 2002-03-21 | 2003-10-02 | Cognis Deutschland Gmbh | Ölphasen für kosmetische Mittel |
DE10213957A1 (de) | 2002-03-28 | 2003-10-09 | Beiersdorf Ag | Vernetzte kosmetische oder pharmazeutische phospholipidhaltige Gele und Emulsionen auf der Basis von ethylenoxidhaltigen oder propylenoxidhaltigen Emulgatoren |
US7811594B2 (en) | 2002-03-28 | 2010-10-12 | Beiersdorf Ag | Crosslinked oil droplet-based cosmetic or pharmaceutical emulsions |
DE10217474A1 (de) | 2002-04-19 | 2003-11-06 | Cognis Deutschland Gmbh | Sonnenschutzemulsion mit Schaumspender |
US20060193905A1 (en) | 2002-05-14 | 2006-08-31 | University Of Louisville Research Foundation, Inc. | Direct cellular energy delivery system |
US7939098B2 (en) * | 2002-05-23 | 2011-05-10 | Femina Pharma Incorporated | Compositions and method for transmucosal drug delivery and cryoprotection |
DE10223486A1 (de) | 2002-05-27 | 2003-12-11 | Beiersdorf Ag | Kosmetische und/oder dermatologische Zubereitung mit 2,3-Dibenzylbutyrolactonen |
EP1371355B1 (en) | 2002-06-03 | 2006-08-02 | Ciba SC Holding AG | UV-protection formulations |
DE10226018A1 (de) | 2002-06-12 | 2003-12-24 | Cognis Deutschland Gmbh | Zubereitungen mit konjugiertem Linolalkohol |
US7147841B2 (en) | 2002-06-17 | 2006-12-12 | Ciba Specialty Chemicals Corporation | Formulation of UV absorbers by incorporation in solid lipid nanoparticles |
AU2003246592A1 (en) | 2002-06-26 | 2004-01-19 | Europroteome Ag | Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases |
US6953786B2 (en) | 2002-10-01 | 2005-10-11 | The Regents Of The University Of California | Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof |
EP1421929A3 (de) | 2002-11-21 | 2004-11-24 | Cognis Deutschland GmbH & Co. KG | Emollients und kosmetische Zubereitungen |
DE10256881A1 (de) | 2002-12-05 | 2004-06-24 | Beiersdorf Ag | Neue topische Verwendung von Bis-Arylimidazo[1,2-a]thiolanderivaten |
US20040110848A1 (en) | 2002-12-10 | 2004-06-10 | Peffley Dennis M | Method and kit for treating cancer |
CN1738592A (zh) | 2003-01-20 | 2006-02-22 | 西巴特殊化学品控股有限公司 | 作为uv吸收剂的三嗪衍生物 |
WO2004069216A1 (en) | 2003-02-03 | 2004-08-19 | Dsm Ip Assets B.V. | Novel stabilized cinnamic ester sunscreen compositions |
US7258876B2 (en) | 2003-02-05 | 2007-08-21 | Craig Bozzacco | Topical composition for treating infectious conditions of skin and mucosa |
CN1208052C (zh) | 2003-03-20 | 2005-06-29 | 上海家化联合股份有限公司 | 一种辅酶q10前体脂质体及其制备方法 |
EP1606270B1 (en) | 2003-03-24 | 2013-08-14 | Basf Se | Symmetrical triazine derivatives |
US7438903B2 (en) | 2003-06-06 | 2008-10-21 | Nbty, Inc. | Methods and compositions that enhance bioavailability of coenzyme-Q10 |
US20050000726A1 (en) | 2003-06-06 | 2005-01-06 | Honda Motor Co., Ltd. | Resin encapsulated electronic component unit and method of manufacturing the same |
US20060035981A1 (en) | 2003-08-02 | 2006-02-16 | Mazzio Elizabeth A | Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment |
US20080069779A1 (en) | 2003-08-04 | 2008-03-20 | Foamix Ltd. | Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof |
US20050036976A1 (en) | 2003-08-12 | 2005-02-17 | Joel Rubin | Topical skin care composition |
JP2007503418A (ja) | 2003-08-27 | 2007-02-22 | バイヤースドルフ・アクチエンゲゼルシヤフト | 局所使用中に個別には感知不能になる外皮を有するカプセル |
WO2005032278A1 (en) | 2003-09-29 | 2005-04-14 | Soft Gel Technologies, Inc. | SOLUBILIZED CoQ-10 |
US8124072B2 (en) | 2003-09-29 | 2012-02-28 | Soft Gel Technologies, Inc. | Solubilized CoQ-10 |
US7169385B2 (en) | 2003-09-29 | 2007-01-30 | Ronald G. Udell | Solubilized CoQ-10 and carnitine |
WO2005030169A1 (en) | 2003-10-02 | 2005-04-07 | Sembiosys Genetics Inc. | Methods for preparing oil bodies comprising active ingredients |
DE10347218A1 (de) | 2003-10-10 | 2005-05-12 | Cognis Deutschland Gmbh | Sonnenschutzmittel |
DE10347940A1 (de) | 2003-10-15 | 2005-05-19 | Cognis Deutschland Gmbh & Co. Kg | Selbstemulgierende Zubereitungen |
CN1870982B (zh) | 2003-10-31 | 2010-05-26 | 株式会社钟化 | 含还原型辅酶q的组合物 |
AU2004290493B2 (en) | 2003-11-05 | 2009-09-24 | Dsm Ip Assets B.V. | Light protecting composition with reduced total amount of UV filter containing a polysiloxane-based UV filter |
US20050100537A1 (en) | 2003-11-10 | 2005-05-12 | Evans Gregory S. | Methods and kits for reducing cellular damage, inhibiting free radical production, and scavenging free radicals in mammals |
DE20320413U1 (de) | 2003-11-17 | 2004-08-26 | Beiersdorf Ag | Kosmetikum mit empfindlichen Inhaltsstoffen |
MXPA06008293A (es) | 2004-01-22 | 2007-06-11 | Univ Miami | Formulaciones topicas de coenzima q10 y metodos de uso. |
US20050226947A1 (en) | 2004-02-04 | 2005-10-13 | Dale Kern | Agents for sequestering serum aging factors and uses therefore |
NZ549159A (en) | 2004-02-19 | 2011-01-28 | Chemaphor Inc | Topical formulations for the treatment of skin conditions |
US7780873B2 (en) | 2004-02-23 | 2010-08-24 | Texas A&M University System | Bioactive complexes compositions and methods of use thereof |
DE102004014615A1 (de) | 2004-03-23 | 2005-10-13 | Beiersdorf Ag | Taurinhaltige Zubereitungen zur Verbesserung der Hautbarriere |
EP1734915A2 (en) | 2004-04-06 | 2006-12-27 | Basf Aktiengesellschaft | COSMETIC FORMULATIONS COMPRISING ZnO NANOPARTICLES |
US20050226858A1 (en) | 2004-04-09 | 2005-10-13 | Kaneka Corporation | Compositions containing reduced coenzyme Q10 and carotenoid |
US7723569B2 (en) | 2004-04-30 | 2010-05-25 | National Institute Of Agrobiological Sciences | Method for producing ubiquinone-10 in plant |
WO2005111224A2 (en) | 2004-05-18 | 2005-11-24 | Kemijski Institut | Water-soluble coenzyme q10 in inclusion complex with beta-cyclodextrin, process of preparing, and use thereof |
DE502005006284D1 (de) | 2004-05-24 | 2009-01-29 | Basf Se | Keratin-bindende polypeptide |
CN101005828B (zh) * | 2004-06-17 | 2012-01-11 | 维尔恩公司 | 用于经粘膜递送活性成分的包含粘膜粘附蛋白和所述活性物质的组合物 |
EP1761271B1 (en) | 2004-06-18 | 2008-12-03 | Symrise GmbH & Co. KG | Blackberry extract |
JP2008504319A (ja) | 2004-06-28 | 2008-02-14 | ディーエスエム アイピー アセッツ ビー.ブイ. | タンパク質水解物を含有する化粧品組成物 |
JP2006070016A (ja) | 2004-08-02 | 2006-03-16 | Kaneka Corp | 還元型補酵素qを含有する美白用組成物 |
US20060051462A1 (en) | 2004-09-03 | 2006-03-09 | Wang Jimmy X | Self emulsifying compositions for delivering lipophilic coenzyme Q10 and other dietary ingredients |
US7288263B2 (en) * | 2004-09-13 | 2007-10-30 | Evera Laboratories, Llc | Compositions and methods for treatment of skin discoloration |
US20060121016A1 (en) | 2004-10-18 | 2006-06-08 | Lee Raphael C | Methods and compositions for treatment of free radical injury |
EP1807452B1 (en) | 2004-11-02 | 2013-05-08 | DSM IP Assets B.V. | Additive for uv-sunscreen preparations |
GB0424891D0 (en) | 2004-11-11 | 2004-12-15 | Boots Co Plc | Topical compositions |
US20060127384A1 (en) | 2004-12-09 | 2006-06-15 | Sergio Capaccioli | Coenzyme Q10 as antiapoptotic agent |
NO20045674D0 (no) | 2004-12-28 | 2004-12-28 | Uni I Oslo | Thin films prepared with gas phase deposition technique |
US20060286046A1 (en) | 2005-01-05 | 2006-12-21 | Haber C Andrew | Skin care compositions |
WO2006073190A1 (ja) * | 2005-01-07 | 2006-07-13 | Rohto Pharmaceutical Co., Ltd. | 外用組成物 |
US20080207560A1 (en) * | 2005-01-07 | 2008-08-28 | Ayako Harada | Composition For External Use |
US20060188492A1 (en) | 2005-01-13 | 2006-08-24 | Chronorx Llc, An Alaska Limited Liability Company | Topical management of ocular and periocular conditions |
DE102005007980A1 (de) | 2005-02-22 | 2006-02-23 | Clariant Gmbh | Kosmetische, pharmazeutische oder dermatologische Zubereitungen enthaltend Copolymerwachse |
EP1871389A2 (en) | 2005-04-01 | 2008-01-02 | Zymes, LLC | Skin enrichment using coq10 as the delivery system |
US20070053985A1 (en) | 2005-08-24 | 2007-03-08 | Kaneka Corporation | Coenzyme Q10-containing fine particle with excellent dispersibility |
US20070071779A1 (en) | 2005-09-26 | 2007-03-29 | Leggit Ingenuity, Llc | Compositions for delivering lipophilic agents to the intestinal mucosa and method of making thereof |
US20070092469A1 (en) | 2005-10-26 | 2007-04-26 | Eric Jacobs | Topically applied Glucosamine Sulfate and all its related, precursor, and derivative compounds significantly increases the skin's natural produciton of hyaluronic acid for the rejuvenation of healthier younger-looking skin; while PhosphatidylCholine is required to replace its deficiency caused by topical Dimethylaminoethanol (DMAE) |
US8506956B2 (en) | 2005-10-31 | 2013-08-13 | Kaneka Corporation | Method for stabilizing reduced coenzyme Q10 |
US9265792B2 (en) | 2005-11-16 | 2016-02-23 | Patricia A. Riley | Integument cell regeneration formulation |
JP2009521408A (ja) | 2005-12-02 | 2009-06-04 | サートリス ファーマシューティカルズ, インコーポレイテッド | Cdc2様キナーゼ(CLK)のモジュレータおよびその使用方法 |
US20070172436A1 (en) | 2006-01-23 | 2007-07-26 | Jerry Zhang | Nonaqueous ascorbic acid compositions and methods for preparing same |
US20070184076A1 (en) | 2006-02-07 | 2007-08-09 | Unger Evan C | Liquid-filled nanodroplets for anti-cancer therapy |
US20070184041A1 (en) | 2006-02-09 | 2007-08-09 | Burja Adam M | Methods and compositions related to production of coenzyme q10 |
US7335384B2 (en) | 2006-03-17 | 2008-02-26 | 4K Nutripharma International | Nutrient compositions for the treatment and prevention of inflammation and disorders associated therewith |
PL2017251T3 (pl) | 2006-04-28 | 2017-12-29 | Kaneka Corporation | Sposób stabilizacji zredukowanego koenzymu Q10 |
WO2007126086A1 (ja) | 2006-04-28 | 2007-11-08 | Kaneka Corporation | 還元型補酵素q10の精製方法 |
US8021659B2 (en) | 2006-04-28 | 2011-09-20 | Naidu Lp | Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof |
US20080020022A1 (en) | 2006-06-05 | 2008-01-24 | Udell Ronald G | Chewable co-enzyme q-10 capsule |
US8894993B2 (en) | 2006-08-04 | 2014-11-25 | Natreon Inc. | Mitochondria-targeted antioxidants |
JP6081195B2 (ja) * | 2009-05-11 | 2017-02-15 | バーグ エルエルシー | エピメタボリックシフター、多次元細胞内分子、または環境影響因子を使用する腫瘍性障害の診断のための方法 |
-
2008
- 2008-03-21 CA CA2823407A patent/CA2823407C/en active Active
- 2008-03-21 MX MX2009010170A patent/MX337408B/es active IP Right Grant
- 2008-03-21 EP EP19192556.9A patent/EP3607937A1/en active Pending
- 2008-03-21 CA CA2680825A patent/CA2680825C/en active Active
- 2008-03-21 WO PCT/US2008/057786 patent/WO2008116135A2/en active Application Filing
- 2008-03-21 MX MX2015000284A patent/MX363435B/es unknown
- 2008-03-21 US US12/052,825 patent/US8454945B2/en active Active
- 2008-03-21 MX MX2013012936A patent/MX352434B/es unknown
- 2008-03-21 EP EP08732635.1A patent/EP2136787B1/en active Active
- 2008-03-21 AU AU2008228764A patent/AU2008228764B2/en active Active
- 2008-03-21 BR BRPI0809164A patent/BRPI0809164B8/pt active IP Right Grant
- 2008-03-21 ES ES08732635T patent/ES2755840T3/es active Active
-
2009
- 2009-09-21 NO NO20093032A patent/NO20093032L/no not_active Application Discontinuation
-
2013
- 2013-01-28 US US13/751,769 patent/US10588859B2/en active Active
-
2014
- 2014-01-06 ZA ZA2014/00071A patent/ZA201400071B/en unknown
- 2014-04-28 AU AU2014202278A patent/AU2014202278C1/en active Active
-
2020
- 2020-02-10 US US16/785,814 patent/US20210015748A1/en not_active Abandoned
-
2022
- 2022-06-23 US US17/847,577 patent/US20230147697A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2008116135A2 (en) | 2008-09-25 |
ES2755840T3 (es) | 2020-04-23 |
BRPI0809164B8 (pt) | 2023-02-28 |
AU2008228764B2 (en) | 2014-05-08 |
CA2680825C (en) | 2013-10-29 |
EP2136787A2 (en) | 2009-12-30 |
AU2014202278C1 (en) | 2017-04-13 |
US10588859B2 (en) | 2020-03-17 |
NO20093032L (no) | 2009-10-22 |
MX363435B (es) | 2019-03-22 |
US8454945B2 (en) | 2013-06-04 |
US20230147697A1 (en) | 2023-05-11 |
MX352434B (es) | 2017-11-24 |
MX2009010170A (es) | 2009-11-26 |
US20130202683A1 (en) | 2013-08-08 |
EP2136787A4 (en) | 2013-07-31 |
US20210015748A1 (en) | 2021-01-21 |
BRPI0809164A2 (pt) | 2014-09-16 |
EP2136787B1 (en) | 2019-08-21 |
EP3607937A1 (en) | 2020-02-12 |
CA2823407A1 (en) | 2008-09-25 |
CA2680825A1 (en) | 2008-09-25 |
AU2014202278B2 (en) | 2016-06-02 |
BRPI0809164B1 (pt) | 2020-08-04 |
AU2008228764A1 (en) | 2008-09-25 |
AU2014202278A1 (en) | 2014-05-22 |
CA2823407C (en) | 2016-10-18 |
ZA201400071B (en) | 2014-12-23 |
WO2008116135A3 (en) | 2008-12-24 |
US20080233183A1 (en) | 2008-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009010170A (es) | Formulaciones topicas que tienen biodisponibilidad aumentada. | |
PH12016500216A1 (en) | Stable pharmaceutical composition and methods of using same | |
MY198422A (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
CR10566A (es) | Compuestos heterociclicos adecuados para el tratamiento de enfermedades relacionadas con nivel elevado de lipidos | |
SG178948A1 (en) | Fatty acid niacin conjugates and their uses | |
IL197080A0 (en) | Pyrimidone compounds as gsk-3 inhibitors | |
IN2012MN02591A (es) | ||
WO2012075081A3 (en) | High-strength testosterone undecanoate compositions | |
MY156288A (en) | Pharmaceutical formulations containing dopamine receptor ligands. | |
MX363178B (es) | Compuestos de carbohidratos con funcion de galactosa para el tratamiento de la nefropatia diabetica y de los trastornos asociados. | |
MX2009009428A (es) | Analogos de ciclopamina heterociclicos y metodos de uso de los mismos. | |
MX2009003911A (es) | Formulaciones de liberacion inmediata, mejoradas de topiramato. | |
MY167691A (en) | A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid | |
UA103930C2 (ru) | Соединения и композиция для лечения паразитарных болезней | |
MY162499A (en) | Methylphenidate-prodrugs, processes of making and using the same | |
MX2013002118A (es) | 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
UA96794C2 (ru) | Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе | |
EP2114415A4 (en) | METHOD AND COMPOUNDS FOR THE TARGETED RELEASE OF ACTIVE SUBSTANCES IN BONES FOR INTERACTION THEREOF | |
EP2099464A4 (en) | LOCAL ADMINISTRATION OF GALLIUM COMPOSITIONS FOR PAIN TREATMENT | |
MX2012013607A (es) | Polisacarido de las semillas de tamarindo para usarse en el tatamiento de enfermedades inflamatorias. | |
MX342459B (es) | 2-oxo- y 2-tioxo-dihidroquinolin-3-carboxamidas sustituidas, como moduladores de kcnq2/3. | |
MX2013002295A (es) | 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
MX336980B (es) | Combinacion y composicion para el tratamiento de obesidad. | |
MX2009002717A (es) | Composiciones y metodos para tratamiento del sindrome de fatiga cronica y enfermedades neurodegenerativas. | |
TNSN08062A1 (en) | Microparticle compositions of the topoisomerase i inhibitor 7-tert-butoxyiminomethylcamptothecin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HH | Correction or change in general | ||
FG | Grant or registration | ||
HC | Change of company name or juridical status |
Owner name: KEYSTONE DENTAL, INC. |